MRKR - Marker Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

MRKR

MARKER THERAPEUTICS, INC.

NASDAQ

$1.37

▼ DOWN 6.16% (-0.09)

KEY STATISTICS

Market Cap$22.84 M

52w High$2.46

52w Low$0.83

Dividend Yield—

Frequency—

P/E-2.91

Volume84.41K

Shares Out.16.67M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Juan F. Vera

COMPENSATION 2026

Salary$415,385

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$741,190

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 16, 2002

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$2.12M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2023-01-27	Reverse	1:10
2016-09-16	Reverse	1:12
2014-02-25	Reverse	1:100
2009-07-31	Reverse	1:10
2009-07-27	Reverse	1:10
2008-04-04	Reverse	2:5
2007-06-28	Reverse	2:5

PRICE

$1.37 ▼ DOWN 6.16% (−$0.09)

OVERLAYS

About Marker Therapeutics, Inc.

https://www.markertherapeutics.com ↗

Marker Therapeutics, Inc. is a Houston-based clinical-stage company developing T cell-based immunotherapies and peptide vaccines for hematologic and solid tumors, including autologous, allogeneic, and off-the-shelf products.

INDUSTRY

Biotechnology

A PRODUCT MARKER THERAPEUTICS, INC. IS KNOWN FOR

MT-601

MT-601 is a clinical-stage multiTAA-specific T cell therapy targeting various cancers, primarily lymphoma, using a patient's own T cells to attack tumor cells, advancing Marker Therapeutics' immunotherapy pipeline.